Compare PLUG & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUG | KLRA |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 1999 | 2026 |
| Metric | PLUG | KLRA |
|---|---|---|
| Price | $2.29 | $17.28 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $2.31 | N/A |
| AVG Volume (30 Days) | ★ 57.5M | 525.5K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $709,919,000.00 | N/A |
| Revenue This Year | $26.67 | N/A |
| Revenue Next Year | $8.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.90 | N/A |
| 52 Week Low | $1.41 | $16.39 |
| 52 Week High | $4.58 | $23.82 |
| Indicator | PLUG | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 40.25 |
| Support Level | $2.11 | $16.39 |
| Resistance Level | $2.50 | $19.13 |
| Average True Range (ATR) | 0.15 | 1.00 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 54.37 | 9.83 |
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.